MX2020003041A - Anticuerpos anti-transtiretina. - Google Patents

Anticuerpos anti-transtiretina.

Info

Publication number
MX2020003041A
MX2020003041A MX2020003041A MX2020003041A MX2020003041A MX 2020003041 A MX2020003041 A MX 2020003041A MX 2020003041 A MX2020003041 A MX 2020003041A MX 2020003041 A MX2020003041 A MX 2020003041A MX 2020003041 A MX2020003041 A MX 2020003041A
Authority
MX
Mexico
Prior art keywords
ttr
antibodies
transthyretin
accumulation
amyloidosis
Prior art date
Application number
MX2020003041A
Other languages
English (en)
Inventor
Tarlochan S Nijjar
Jeffrey N Higaki
Robin Barbour
Svetlana Alexander
Joshua Reginald Salmans
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2020003041A publication Critical patent/MX2020003041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion provee anticuerpos que se unen especificamente a transtiretina (TTR). Los anticuerpos pueden ser utilizados para tratar o efectuar la profilaxis de enfermedades o trastornos asociados con acumulacion de TTR o acumulacion de depositos de TTR (por ej. amiloidosis por TTR). Los anticuerpos tambien pueden ser utilizados para diagnosticar amiloidosis por TTR e inhibir o reducir la agregacion de TTR, y para monitorear la eficacia de terapias contra TTR, entre otras aplicaciones.
MX2020003041A 2017-10-06 2018-10-05 Anticuerpos anti-transtiretina. MX2020003041A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762569436P 2017-10-06 2017-10-06
US201762598965P 2017-12-14 2017-12-14
PCT/US2018/054720 WO2019071205A1 (en) 2017-10-06 2018-10-05 ANTI-TRANSTHYRETIN ANTIBODY

Publications (1)

Publication Number Publication Date
MX2020003041A true MX2020003041A (es) 2020-10-05

Family

ID=65994817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003041A MX2020003041A (es) 2017-10-06 2018-10-05 Anticuerpos anti-transtiretina.

Country Status (15)

Country Link
US (1) US11267877B2 (es)
EP (1) EP3691447A4 (es)
JP (1) JP7357609B2 (es)
KR (1) KR20200074956A (es)
CN (1) CN111315213B (es)
AU (1) AU2018345806A1 (es)
BR (1) BR112020006434A2 (es)
CA (1) CA3077361A1 (es)
CU (1) CU24731B1 (es)
MX (1) MX2020003041A (es)
PE (1) PE20210552A1 (es)
SA (1) SA520411703B1 (es)
SG (1) SG11202002489YA (es)
WO (1) WO2019071205A1 (es)
ZA (1) ZA202002141B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
CU24731B1 (es) 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
CU20200042A7 (es) 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
CN115551886A (zh) 2020-05-12 2022-12-30 生物控股有限公司 用于ttr淀粉样变性的联合疗法
CN118059229A (zh) * 2020-10-14 2024-05-24 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
US20240082400A1 (en) * 2021-01-15 2024-03-14 The General Hospital Corporation Cd64 chimeric receptor and uses thereof
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
KR20250006910A (ko) * 2022-04-20 2025-01-13 센티 바이오사이언시스, 인코포레이티드 항원 결합 도메인 및 이의 사용 방법
EP4630812A1 (en) 2022-12-05 2025-10-15 Neurimmune AG Cyclic compounds and their use in assays for detecting antibodies
WO2024240562A1 (en) * 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
CN121646476A (zh) 2023-06-07 2026-03-10 神经免疫有限公司 用于治疗淀粉样变性的疫苗
CN121487964A (zh) * 2023-06-14 2026-02-06 艾慕特林有限公司 抗原纤维抗体
CN120860019A (zh) * 2024-04-30 2025-10-31 厦门大学 氯苯唑酸在激活rxr活性中的用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7485616B2 (en) 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
WO2004024090A2 (en) 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
CA2538076A1 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
US8236933B2 (en) * 2005-04-13 2012-08-07 Garvan Institute Of Medical Research Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
ATE495447T1 (de) 2006-07-03 2011-01-15 Univ Johns Hopkins Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie
EP2548647B1 (en) 2006-10-20 2018-08-15 CLONDIAG GmbH Assay devices and methods for the detection of analytes
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
AU2009301580B2 (en) 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
JP2010195710A (ja) 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
AU2010220781A1 (en) 2009-03-02 2011-10-06 The University Of British Columbia Antibodies and epitopes specific to misfolded prion protein
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2953970A4 (en) * 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
DK2995680T3 (en) * 2013-03-12 2018-12-17 Univ Nagoya Nat Univ Corp PROCEDURE FOR INCREASING PHOTOSYNTHESIS AND PLANTS OF PLANTS
EP3022225B1 (en) 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
US10344080B2 (en) * 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
EP3981874A1 (en) 2014-01-29 2022-04-13 KM Biologics Co., Ltd. Anti-transthyretin human antibody
EP3101131B1 (en) * 2014-01-29 2020-08-19 KM Biologics Co., Ltd. Anti-transthyretin humanized antibody
DK3185957T3 (da) 2014-08-29 2022-08-29 Alnylam Pharmaceuticals Inc Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
CU24731B1 (es) 2017-10-06 2025-01-15 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
CU20200042A7 (es) 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
WO2021168156A1 (en) 2020-02-20 2021-08-26 Prothena Biosciences Limited Monitoring transthyretin amyloidosis

Also Published As

Publication number Publication date
CU24731B1 (es) 2025-01-15
ZA202002141B (en) 2023-01-25
SG11202002489YA (en) 2020-04-29
CN111315213B (zh) 2023-09-12
EP3691447A4 (en) 2021-08-11
PE20210552A1 (es) 2021-03-17
US11267877B2 (en) 2022-03-08
CN111315213A (zh) 2020-06-19
EP3691447A1 (en) 2020-08-12
SA520411703B1 (ar) 2024-04-28
BR112020006434A2 (pt) 2020-11-03
JP7357609B2 (ja) 2023-10-06
US20200331992A1 (en) 2020-10-22
KR20200074956A (ko) 2020-06-25
CA3077361A1 (en) 2019-04-11
JP2020536532A (ja) 2020-12-17
WO2019071205A1 (en) 2019-04-11
AU2018345806A1 (en) 2020-03-12
CU20200021A7 (es) 2021-01-12

Similar Documents

Publication Publication Date Title
MX2020003041A (es) Anticuerpos anti-transtiretina.
SA517381981B1 (ar) أجسام مضادة لترانس ثيرتين
PH12017501318B1 (en) Anti-transthyretin antibodies
SA517381991B1 (ar) أجسام مضادة لترانس ثيرتين
WO2018007923A3 (en) Anti-transthyretin antibodies
WO2018007924A3 (en) Anti-transthyretin antibodies
WO2018007922A3 (en) Anti-transthyretin antibodies
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
PH12021553109A1 (en) Humanized antibody molecules to cd138 and uses thereof
MX2021011830A (es) Anticuerpo anti fgf23.
MY193688A (en) Anti-transthyretin antibodies
HK1240249A1 (en) Anti-transthyretin antibodies
HK1247132A1 (zh) 识别medin的抗体
EA202090898A1 (ru) Антитранстиретиновые антитела
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
NZ733896B2 (en) Anti-transthyretin antibodies
AR113345A1 (es) Anticuerpos anti-transtiretina
NZ629683A (en) Methods for treating conditions associated with masp-2 dependent complement activation